Outlook Therapeutics, Inc.
OTLK· Nasdaq
OTLKOutlook Therapeutics, Inc.
Filed Feb 14, 2024 · 10-Q · 45 days after period end · 0001558370-24-001172
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Net Income | -$11.18M | -$18.66M | -$14.46M | -$14.46M |
| EPS Diluted | -$0.86 | -$0.08 | -$0.08 | -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Dec 31, 2023 · filed Feb 14, 2024 · 45 d after period end
